This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
D-Lysergic acid ethylamide (LAE-32) is a derivative of ergine.[1][2] It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.5 milligrams.
![]() | |
Clinical data | |
---|---|
Other names | LAE; Lysergic acid ethylamide; d-Lysergic acid ethylamide; d-Ethyllysergamide, |
Routes of administration | Oral |
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H21N3O |
Molar mass | 295.386 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder.
References
edit- ^ "N-Ethyllysergamide". PubChem. U.S. National Library of Medicine. Retrieved 2022-11-16.
- ^ Baquiran M, Al Khalili Y (2022). "Lysergic Acid Diethylamide Toxicity". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31985997. Retrieved 2022-11-18.